Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. 

For the full press release, click here

For the Journal Article, click here

Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada. 

Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  

For the full press release, click here

September 09, 2016 - Toronto: To celebrate International PBC Day on September 11, 2016, Self Care Catalysts -- a patient intelligence and solutions company -- is announcing its newest self-care mobile app, created to support patients diagnosed with Primary Biliary Cholangitis (PBC). The team at Self Care Catalysts worked closely with the Canadian PBC Society to create a customized suite of self-care tools to support the total care for PBC, and to empower patients to play an active role in tracking their health story -- so that more can be understood about this rare disease.

For the full press release, click here

100 brains, 50 locations all for 1 important cause: Brain Health!

The art installations can be found across Toronto and highlight the importance of brain health with the aim to improve the quality of life for those with dementia and other neurological disorders.

The project is being delivered by the Baycrest Foundation who see the project as a"catalyst for discussion and awareness of brain health."

Learn more here

Find a Brain Installation here

Innovation Partnership: Procurement by Co-Design is a unique program that offers healthcare-service providers something rare: the opportunity to participate in the development of technology tailor-made for them—solutions that address the particular problems they often face—and then actually procure these solutions.

For more information click here

Aug 18, 2016 - Vancouver - Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zymeworks’ lead investigational products ZW25 and ZW33 for the treatment of ovarian cancer. 

For the full press release, click here

Aug 17, 2016 TORONTO - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides. 

For the full press release, click here

Aug 15, 2016 - Toronto: Profound Medical Corp. (TSXV:PRN), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer.  Steven Plymale, the Company’s current CEO, will transition to President and Chief Operating Officer.

For the full press release, click here

Aug 16, 2016 - TORNTO - Genesys Capital has collected almost three-quarters of the $125 million target set for its third venture fund, adding to the momentum felt of late in Canada’s life-sciences sector.

Genesys Ventures III initially closed at $90 million in committed capital, the Toronto firm said today. It is expected to reach its goal early next year, Managing Director Damian Lamb told PE Hub Canada. 

Should the fund reach its $125 million target, it will be the largest Genesys has raised in its 16-year history.

For the full article, click here

August 15, 2016 Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves. The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine.

For the full release click here

Aug 12, 2016 TORONTO - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

For the full press release, click here

August 3, 2016, London Ontario – The Centre for Imaging Technology Commercialization (CIMTEC) is pleased to announce the appointment of Greg Hood as Chief Executive Officer, effective immediately.

July 5, 2016 TORONTO – Synaptive Medical Inc., a company focused on global commercialization of innovative solutions, announced the approval from Health Canada to market BrightMatterTM Guide. This new technology is part of a solution for health care providers that includes informatics, imaging, surgical planning, navigation and advanced optics.

July 4, 2016, TORONTO - Ontario's $20 million Health Technologies Fund (HTF) is open for business.

Announced in May by William Charnetski, Ontario's Chief Health Innovation Strategist, the Fund will support the development of leading, market-ready, made-in-Ontario health technologies by accelerating prototyping, evaluation, adoption and diffusion in the Ontario health care sector.

June 29, 2016, London ON – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).

June 27, 2016 LONDON, ONTARIO Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.

June 21, 2016 LONDON, ONTARIO – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.

Canadian Manufacturers & Exporters congratulates Valeant Canada on its $27.5 million commitment to expand manufacturing operations in Canada.

For the full article click here